ELSPBP1 Inhibitors
ELSPBP1 inhibitors are a class of chemical compounds that interact with various signaling pathways and biological processes to indirectly inhibit the functional activity of the ELSPBP1 protein. These inhibitors achieve this by targeting proteins and enzymes that play a crucial role in the pathways where ELSPBP1 is known to be involved. For instance, Staurosporine, a kinase inhibitor, has a broad target range but notably inhibits protein kinase C (PKC), which is a key player in the signaling cascade that influences ELSPBP1's activities. The inhibition of PKC by Staurosporine consequently leads to a decrease in ELSPBP1's functional activities. LY294002 and Wortmannin are both inhibitors of PI3K, which is an upstream regulator of the Akt signaling pathway. By inhibiting PI3K, these compounds reduce Akt activity, which is pivotal for cell survival and proliferation signals where ELSPBP1 is implicated. Consequently, ELSPBP1's role in mediating these signals is diminished.
Further, compounds like U0126 and PD98059 target the MAPK/ERK pathway by inhibiting MEK1/2, which is essential for the transmission of signals within this pathway, affecting ELSPBP1's capacity to participate in signal transduction. Similarly, SB203580 and SP600125 inhibit p38 MAPK and JNK, respectively, which are involved in the cellular stress response and apoptosis, processes in which ELSPBP1 is potentially active. By blocking these kinases, the inhibitors impair the pathways' function, leading to decreased activity of ELSPBP1 in these contexts. Moreover, LFM-A13, which inhibits Bruton's tyrosine kinase (BTK), and NSC 23766, which inhibits Rac1, disrupt B-cell receptor signaling and cytoskeletal reorganization, respectively.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases, including protein kinase C (PKC), which ELSPBP1 is known to interact with. ELSPBP1's function is often mediated through its interaction with PKC; thus, staurosporine's inhibition of PKC can lead to a decrease in ELSPBP1's functional activities. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which is upstream of the Akt signaling pathway. ELSPBP1 has been implicated in cell survival pathways that are often regulated by PI3K/Akt signaling. Inhibition of PI3K by LY294002 would lead to reduced Akt activity and thus reduce ELSPBP1 mediated cell survival signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in regulating cell growth and proliferation, which can affect ELSPBP1 function indirectly since ELSPBP1 is involved in these cellular processes. Reduced mTOR activity can decrease ELSPBP1's role in promoting cell growth and survival. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are integral components of the MAPK/ERK pathway. ELSPBP1 has been shown to play a role in signal transduction through this pathway. Inhibition of MEK1/2 can disrupt the pathway's function, leading to decreased activity of ELSPBP1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP Kinase. ELSPBP1 is involved in stress response pathways regulated by p38 MAPK. By inhibiting p38 MAPK, SB203580 can interfere with stress signal transduction processes that would typically involve ELSPBP1, leading to reduced functional activity of ELSPBP1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K like LY294002. It prevents the phosphorylation and activation of Akt, which is important for many cell survival and growth signals where ELSPBP1 may be involved. Inhibition of PI3K/Akt pathway by wortmannin can lead to a decrease in ELSPBP1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is a kinase involved in the MAPK/ERK pathway. Since ELSPBP1 is associated with signal transduction through this pathway, inhibition of MEK by PD98059 can suppress the activity of ELSPBP1 by limiting the pathway's downstream signaling effects. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can regulate apoptosis and other cellular processes that ELSPBP1 may influence. By inhibiting JNK, SP600125 can reduce the ability of ELSPBP1 to affect these processes, leading to decreased ELSPBP1 activity. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
LFM-A13 is a specific inhibitor of Bruton's tyrosine kinase (BTK). BTK is involved in the B-cell receptor signaling pathway, which can intersect with pathways involving ELSPBP1. Inhibition of BTK by LFM-A13 can lead to impaired signaling where ELSPBP1 is functionally active. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits Rac1 activation, which is involved in actin cytoskeleton reorganization. ELSPBP1 has functions linked to cytoskeletal arrangements, and by inhibiting Rac1, NSC 23766 can disrupt processes that require ELSPBP1 activity, leading to its functional inhibition. | ||||||